Autres langues Aeterna Zentaris Inc.

Actions

AEZS

CA0079755017

Temps Différé Toronto S.E. Autres places de cotation 18:07:18 29/04/2024			Varia. 5j.	Varia. 1 janv.
2,67 ^CAD	+0,75 %		+0,38 %	+3,89 %

27/03	Aeterna Zentaris déclare une perte nette de 5,6 millions $ US au quatrième trimestre et fait le point sur l'étude DETECT	MT
27/03	Aeterna Zentaris Inc. annonce ses résultats pour l'exercice terminé le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

North American Morning Briefing : Powell Awaited -2-	03/04
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28/03
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28/03
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27/03
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03
Aeterna Zentaris : Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Form 6-K	27/03
Aeterna Zentaris : Consolidated Financial Statements As of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 - Form 6-K	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
North American Morning Briefing : Markets on Hold -2-	20/03
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	12/03
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	26/02
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro	15/02
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell	18/12
Top Premarket Gainers	18/12
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders	14/12
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	14/12
Canadian Investment Regulatory Organization Trade Resumption - AEZS	14/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aeterna Zentaris Inc.

Actions

AEZS

CA0079755017

Autres langues

Filtres